Core Viewpoint - The announcement highlights that the application for the innovative traditional Chinese medicine, Yushuda Tablets, has been accepted by the National Medical Products Administration of China, indicating a significant step towards its market introduction [1] Group 1: Product Development - Yushuda Tablets are designed to invigorate the spleen, transform dampness, and regulate qi, showing significant efficacy in alleviating symptoms of emotional distress such as depression [1] - Clinical studies confirm that Yushuda Tablets demonstrate notable effectiveness, particularly in improving early mild to moderate depressive symptoms [1] Group 2: Clinical Trials - The Phase III clinical trial results completed by Tongjitang Pharmaceutical in 2024 indicate that Yushuda Tablets exhibit good safety and efficacy in treating mild to moderate depression [1] - The efficacy of Yushuda Tablets is reported to be significantly superior to that of the placebo group [1]
中国中药：国家药监局受理郁枢达片的新药注册上市申请